Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up: Implication of a link between VEGF pathway and tamoxifen response

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: id:"swepub:oai:DiVA.org:umu-5966" > Tumor-specific VEGF...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Rydén, LisaLund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund (author)

Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up : Implication of a link between VEGF pathway and tamoxifen response

Article/chapterEnglish2005

Publisher, publication year, extent ...

The Hague :Nijhoff,2005
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:umu-5966
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-5966URI
https://doi.org/10.1007/s10549-004-1655-7DOI
https://lup.lub.lu.se/record/133893URI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Vascular endothelial growth factor (VEGF-A) is considered a prognostic indicator for clinical outcome in breast cancer. Conflicting results nevertheless exist and there is a need for larger studies including untreated patients in order to clarify the importance of tumor-specific VEGF-A regarding prognosis as well as potential links to predictive treatment information. VEGF-A and its receptor, vascular endothelial growth receptor 2 (VEGFR2), were therefore analyzed by immunohistochemistry in postmenopausal breast cancers enrolled in a clinical trial where patients were randomized to adjuvant tamoxifen treatment (n=124) for 2 years or no treatment (n=127) with a median follow-up of 18 years. The tumors were arranged in a tumor tissue microarray system enabling parallell analysis of the angiogenic factors and hormone receptor status. Tumor-specific expression of VEGFR2 correlated strongly with expression of VEGF-A and progesterone receptor (PR) negativity, whereas VEGF-A was not associated with hormone receptor status. Among patients with estrogen receptor (ER) positive (fraction > 10%) tumors, there was a statistically significant tamoxifen response in VEGF-A negative tumors at both 10-year and 18-year disease-free survival (DFS), contrasting to VEGF-A positive tumors who had no beneficial effect of tamoxifen. A treatment-interaction variable indicated a marked difference in tamoxifen response depending on VEGFA-status in terms of DFS at 10 and 18 years of follow-up, p=0.046 and p=0.039, respectively. VEGFR2 status did not yield significant predicitve information for tamoxifen response in patients with ER fraction > 10%, whereas in patients with ER fraction > 90% both VEGF-A and VEGFR2 status were associated with tamoxifen treatment effect.

Subject headings and genre

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
Aged
Antineoplastic Agents; Hormonal/*pharmacology/*therapeutic use
Breast Neoplasms/*drug therapy/*pathology
Chemotherapy; Adjuvant
Female
Follow-Up Studies
Humans
Immunohistochemistry
Middle Aged
Postmenopause
Prognosis
Tamoxifen/*pharmacology/*therapeutic use
Treatment Outcome
Tumor Markers; Biological/*analysis
Vascular Endothelial Growth Factor A/*blood
Vascular Endothelial Growth Factor Receptor-2/*blood

Added entries (persons, corporate bodies, meetings, titles ...)

Stendahl, MariaLund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups(Swepub:lu)pat-sma (author)
Jonsson, HåkanUmeå universitet,Kirurgi,Onkologi (author)
Emdin, StefanUmeå universitet,Kirurgi,Onkologi(Swepub:umu)stem0001 (author)
Bengtsson, Nils O.Umeå universitet,Kirurgi,Onkologi (author)
Landberg, GöranLund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups(Swepub:lu)pat-gla (author)
Kirurgi, LundSektion V (creator_code:org_t)

Related titles

In:Breast Cancer Research and TreatmentThe Hague : Nijhoff89:2, s. 135-1430167-68061573-7217

Internet link

Find in a library

Breast Cancer Research and Treatment (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Rydén, Lisa; Stendahl, Maria; Jonsson, Håkan; Emdin, Stefan; Bengtsson, Nils ...; Landberg, Göran

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Articles in the publication: Breast Cancer Re ...

By the university: Umeå University; Lund University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se